Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Pipeline Report H1 2017 - Review of 14 Companies & Drug Profiles Including Celgene, Merck & Pfizer - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2017" report to their offering.

Post-Polycythemia Vera Myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which the bone marrow makes too many red blood cells. It may also result in the overproduction of white blood cells and platelets. Symptoms include heart attack, stroke, deep venous thrombosis, Headaches, lack of concentration and fatigue. The disease may be controlled by chemotherapy, transfusions, transplant and medications.

Pharmaceutical and Healthcare latest pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 10, 4 and 1 respectively.

Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Report Coverage
  3. Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Overview
  4. Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Products under Development by Companies
  8. Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Assessment
  9. Assessment by Target
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Companies Involved in Therapeutics Development
  • Celgene Corp
  • CTI BioPharma Corp
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • Incyte Corp
  • Italfarmaco SpA
  • JW Pharmaceutical Corp
  • MedImmune LLC
  • MEI Pharma Inc
  • Merck & Co Inc
  • Nippon Shinyaku Co Ltd
  • Novartis AG
  • Pfizer Inc
  • Promedior Inc

For more information about this report visit http://www.researchandmarkets.com/research/2fbmtg/postpolycythemia

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Leukemia Drugs, Hematological Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Leukemia Drugs, Hematological Drugs